⌕
4D Molecular Therapeutics · FDMT · Nasdaq
Tenet 52 · Mixed
Compare
$10.98−2.79%Market openTenet 52 · Mixed
$10.98−0.31 (−2.79%)
Market open · 15-min delayed · as of 10:59 AM ET· Nasdaq · USD

4D Molecular Therapeutics (FDMT) Stock

4D Molecular Therapeutics (FDMT) has a Tenet Score of 52 of 100 against 439 Healthcare peers, as of Nov 17, 2026.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Market cap
$789.0M
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
6.96 – 16.93
low → high
Tenet Score
52/100
Mixed · 439 Healthcare peers

Industry: Drugs · see every company filed here →

4D Molecular Therapeutics Inc scores 52/100. Mixed. Strongest on value and financial health, quality is the soft spot versus 439 Healthcare peers.

Tenet Score · vs sector

n=439
52/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
69
Quality
21
Health
67
Growth
52

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueCQualityFHealthCGrowthCMomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
2.4×
cap ÷ Sep 30, 2026 book value, Nov 16, 2026 close
P/S
9.6×
price to sales
ROE
−57%
TTM through Sep 30, 2026
Operating margin
−187.2%
fiscal 2025, before interest and tax
Net margin
−208.3%
TTM through Sep 30, 2026
Current ratio
6.15
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 1y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About 4D Molecular Therapeutics Inc

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, car…

Composite computed Nov 17, 2026 · peer basis: Healthcare (n=439) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 59 US ETFs · top wrappers by weightSee all ETFs holding FDMT →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is 4D Molecular Therapeutics in?

4D Molecular Therapeutics is in the Healthcare sector and the Drugs industry.

What is 4D Molecular Therapeutics' Tenet Score?

4D Molecular Therapeutics' Tenet Score is 52 out of 100, ranked against 439 Healthcare peers as of Nov 17, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.